Section 232 tariffs on patented pharmaceuticals took effect Friday for the industry’s largest importers, opening a high stakes test of whether a wall of duties can pull drug manufacturing back to American soil.
WASHINGTON, Aug. 2, 2026. The steepest tariff ever applied to the American medicine cabinet is now being collected at United States ports of entry. At 12:01 a.m. on Friday, July 31, an additional 100 percent duty took effect on imports of patented pharmaceutical products, their active pharmaceutical ingredients, and the key starting materials used to make them, the culmination of a Section 232 national security process that began more than a year ago and that the administration has framed as the centerpiece of its campaign to reshore drug production.
The first wave of the tariff applies to covered products imported by the large multinational drugmakers identified in Annex III of the April presidential proclamation, a list that trade counsel at Arnall Golden Gregory puts at 17 companies and that industry trackers report includes Pfizer, Johnson & Johnson, Merck, Eli Lilly, AbbVie, Amgen, AstraZeneca, Novartis, and Sanofi, among others. For every other importer of covered products, the same 100 percent duty arrives on September 29, 2026, 180 days after the proclamation was issued.
The stakes are difficult to overstate. Patented, brand name medicines account for a large majority of United States drug spending even though they represent a small share of prescriptions filled, and a substantial portion of those products, or the active ingredients inside them, cross a border before they reach an American pharmacy shelf. A branded product that cleared customs duty free in June could, in the absence of an exemption or a reduced rate, face a doubled import cost by fall, a point customs advisers at the Mallory Group have been pressing on importers for weeks.
What Took Effect on Friday
The new duty applies to three categories of goods. First are pharmaceutical articles that are subject to a valid, unexpired United States patent and that appear either in the Food and Drug Administration’s Approved Drug Products with Therapeutic Equivalence Evaluations, universally known as the Orange Book, or in the FDA’s Lists of Licensed Biological Products, known as the Purple Book. Second are the active pharmaceutical ingredients for those articles. Third are the key starting materials from which those ingredients are synthesized.
Annex I of the proclamation identifies the covered products, ingredients, and raw materials by Harmonized Tariff Schedule number, which means the practical question of whether a given entry owes the duty turns on classification work that many importers are still completing. Trade lawyers have warned that the combination of patent status, FDA listing status, and tariff classification makes this one of the most technically demanding tariff actions ever administered by United States Customs and Border Protection.
The duty is an additional 100 percent, stacked on top of whatever most favored nation rate otherwise applies. For products of certain trading partners the proclamation prescribes lower additional rates, discussed below, but the headline figure is the one the White House has promoted: a dollar for dollar penalty on every dollar of declared value for covered patented medicines from most of the world.
A Fifteen Month Road to 100 Percent
The legal foundation for Friday’s action was poured in the spring of 2025. On April 1 of that year, the Department of Commerce initiated a Section 232 investigation into imports of pharmaceuticals, pharmaceutical ingredients, and their derivative products. Section 232 of the Trade Expansion Act of 1962 authorizes the president, following a Commerce investigation, to adjust imports that are found to threaten to impair national security, the same authority used for the administration’s steel, aluminum, copper, and semiconductor programs.
Commerce concluded that pharmaceuticals and their ingredients are being imported into the United States in such quantities and under such circumstances as to threaten national security, and in early April 2026 the White House issued the proclamation announcing the 100 percent duty with a 120 day runway for the Annex III companies and a 180 day runway for everyone else. The two step schedule was deliberate. It put the largest importers, the companies the administration most wants at the negotiating table, on the shortest clock, while giving smaller firms until the end of September to reorganize supply chains or seek shelter under one of the proclamation’s many carve outs.
The pharmaceutical action also needs to be read against the administration’s parallel push on drug pricing. Thirteen companies listed in Annex II of the proclamation that entered most favored nation pricing agreements with the Department of Health and Human Services are exempt from the additional duty entirely until January 20, 2029. The message to the industry was explicit: sign a pricing deal, commit to build in America, and the tariff disappears; hold out, and your imports double in cost.
A Tiered and Exemption Riddled Structure
For all the severity of the headline rate, the proclamation is shot through with reduced rates and exemptions that will determine its real world bite. Analysts at PharmaSource captured the dynamic in a briefing titled, in effect, a 100 percent headline rate with a far lower real world impact, noting the dozens of exceptions written into the order.
Products of the European Union, Japan, South Korea, Switzerland, and Liechtenstein face a 15 percent additional rate rather than 100 percent, a concession that reflects the trade and security frameworks Washington has negotiated with those partners. Products of the United Kingdom face 10 percent under the bilateral agreement concluded with London. Companies that have an onshore production plan approved by the secretary of Health and Human Services pay a 20 percent additional rate until April 30, 2030, a discount designed to reward firms that are actually pouring concrete for American plants rather than merely promising to.
A further category of specialty products pays no additional duty at all. That zero rate covers drugs designated as orphan products under the Orphan Drug Act for all approved indications, nuclear medicines, plasma derived therapies, fertility treatments, cell and gene therapies, antibody drug conjugates, and medical countermeasures related to chemical, biological, radiological, and nuclear threats, along with other specialty products the secretary of Commerce may identify and certain animal health products from partner jurisdictions.
Finally, and most consequentially for public health, the action does not touch generic medicines. Generic pharmaceuticals and their associated ingredients, defined as FDA approved articles not subject to a valid, unexpired United States patent and off exclusivity, are excluded, as are United States origin products and a list of goods identified by tariff code in Annex IV. Because roughly nine in ten American prescriptions are filled with generics, the administration has argued that the tariff targets the high margin branded segment while sparing the medicines most price sensitive patients rely on.
Who Pays First, and Who Escapes
The architecture of exemptions means Friday’s effective date lands very differently across the industry. The 13 Annex II companies with most favored nation pricing agreements have bought themselves total relief through January 2029. Companies with approved onshoring plans have converted a 100 percent exposure into a 20 percent one. Firms whose portfolios skew toward orphan drugs, biologic specialty products, or generics may find their effective exposure surprisingly modest.
That leaves a distinct set of losers: large branded manufacturers on the Annex III list that have neither signed a pricing agreement nor obtained approval of an onshoring plan, and whose covered products originate outside the favored jurisdictions. For those companies, the arithmetic is brutal. A patented product with a declared customs value of 50 dollars per unit now owes an additional 50 dollars at the border before any other duty is counted.
Trade counsel at Crowell & Moring, Ropes & Gray, Foley Hoag, and other firms tracking the action have emphasized in client advisories that the tiered structure effectively converts a tariff into a negotiation. Because the rate a company pays depends on agreements it can still sign, the proclamation functions as a standing offer: pricing concessions and capital commitments in exchange for tariff relief. Several firms note that this is a novel use of Section 232, which has historically imposed uniform rates by product and country rather than rates that vary company by company.
Industry Reaction: Compliance Scramble and Quiet Lobbying
Public reaction from the largest manufacturers has been muted, in part because so many of them are in active negotiations with the Department of Health and Human Services and the Department of Commerce over pricing agreements and onshoring plans that could zero out or shrink their exposure. Industry advisers describe a two track response: loud compliance work and quiet diplomacy.
On the compliance track, customs brokers and law firms report a surge of demand for tariff classification assessments, country of origin studies, and exemption eligibility reviews. Arnall Golden Gregory’s international trade team, in guidance published ahead of the deadline, urged companies to confirm the Harmonized Tariff Schedule classification of every imported product, determine whether articles qualify as generics or specialty products outside the action’s scope, verify country of origin for goods claiming the reduced European, Japanese, Korean, Swiss, or British rates, and evaluate duty drawback and deferral strategies.
The enforcement risk is real. Customs and Border Protection is expected to rely on importer declarations, tariff classifications, and supporting documentation, with heightened scrutiny of pharmaceutical entries where patent status, origin, or classification is unclear. Misclassification, whether of patent status, origin, or exemption eligibility, can trigger penalties, retroactive duty assessments, and enforcement actions. In a month when CBP announced it had uncovered more than 1 billion dollars in evaded duties under the Enforce and Protect Act, no importer wants to be the test case for pharmaceutical tariff evasion.
Hospital systems, insurers, and pharmacy benefit managers have been more openly anxious. Their concern is less the tariff itself than the pass through: how much of a doubled import cost for a branded biologic will surface in list prices, premiums, and hospital acquisition costs over the next several quarters. Health economists caution that branded drug pricing is only loosely tethered to import cost, since list prices already sit far above marginal cost, but sustained tariff pressure on active ingredients and starting materials is harder for manufacturers to absorb invisibly.
The Economics of a Doubled Import Price
The macroeconomic question hanging over the action is whether a tariff, even one this large, can relocate an industry whose capital cycles run in decades. Building and validating a pharmaceutical manufacturing plant in the United States is a multiyear undertaking involving FDA inspection and approval, specialized labor, and supply chains for reagents and equipment that are themselves global. Skeptics argue that companies will pay the 20 percent onshoring rate, or the 15 percent allied rate, and treat it as a cost of doing business rather than uproot production.
Supporters counter that the proclamation’s incentives are already working, pointing to the wave of announced United States manufacturing investments from major drugmakers over the past year and to the most favored nation pricing agreements that the tariff threat helped extract. On this view the tariff is less a revenue measure than a forcing device, and the fact that so many companies have negotiated their way to lower rates is evidence of success, not failure.
The near term price effects will be watched closely. Because the first wave applies to the largest companies, which also have the greatest capacity to shift production, stockpile inventory, and negotiate exemptions, the initial customs data may understate the eventual impact. Importers built inventories aggressively ahead of the deadline, according to freight forwarders serving the sector, a pattern familiar from every major tariff action of the past two years. Those buffers typically run down within one or two quarters.
There is also a supply resilience argument cutting in both directions. The administration contends that dependence on foreign made ingredients, particularly for essential medicines, is itself a national security vulnerability that the tariff corrects. Critics respond that layering a 100 percent duty on top of an already strained global supply chain raises the risk of shortages and discontinuations for lower margin products, and that the exemption for generics, while welcome, does not protect branded products that lack therapeutic substitutes.
What Importers and Exporters Should Do Now
For companies in the pharmaceutical supply chain, the compliance agenda between now and September 29 is concrete. Importers not on the Annex III list should use the remaining weeks to map their exposure: identify every entry line that could fall within Annex I, confirm patent and FDA listing status for each product, and document country of origin with the rigor CBP will expect for claims to the reduced allied rates.
Companies with plausible claims to the specialty product zero rate, particularly for orphan designated drugs, cell and gene therapies, and plasma derived products, should assemble the supporting record now rather than at the first CBP request for information. Firms weighing an onshoring plan application face a genuine strategic decision, since an approved plan cuts the rate to 20 percent through April 2030 but comes with commitments the government will monitor.
Foreign exporters, especially in India and China for starting materials and in Europe for finished branded products, should expect their United States customers to push aggressively for origin documentation, price renegotiation, and in some cases relocation of final manufacturing steps. The proclamation’s structure rewards moving the last, value defining stages of production either to the United States or to a favored jurisdiction, and contract manufacturers in those locations are already marketing themselves accordingly.
The Road Ahead
Three dates now structure the industry’s planning. September 29, 2026 brings the second wave, extending the 100 percent duty to all remaining importers of covered products. January 20, 2029 ends the blanket exemption for the 13 companies with most favored nation pricing agreements, unless those arrangements are renewed or replaced. April 30, 2030 ends the reduced 20 percent rate for companies with approved onshoring plans, by which point the administration expects domestic capacity to be operating at scale.
Litigation remains a wild card. The Supreme Court’s decision in February striking down the tariffs imposed under the International Emergency Economic Powers Act confirmed that the courts will police the statutory boundaries of trade authority, and Section 232 actions have drawn constitutional and procedural challenges before. But the courts have historically given Section 232 wide latitude, and no challenge filed to date has stopped a metals tariff imposed under the same authority.
What is certain is that the United States has, for the first time, made the price of importing a patented medicine a direct instrument of industrial and pricing policy. Whether that instrument reshores an industry or simply reprices one will be the defining trade policy question for the pharmaceutical sector for the rest of the decade, and the first hard evidence starts accumulating in the customs data now.
A Crowded Tariff Landscape
The pharmaceutical duties arrive in the middle of the most active month for United States trade policy since the spring of 2025. On July 24, new Section 301 tariffs of 10 to 12.5 percent took effect on goods from 60 trading partners following the administration’s forced labor investigations, replacing the temporary 10 percent global surcharge that had been imposed under Section 122 of the Trade Act after the Supreme Court struck down the tariffs previously collected under the International Emergency Economic Powers Act. A separate Section 301 action placed a 25 percent duty on a wide range of Brazilian goods on July 22, and additional duties on Canadian products are scheduled for August 19.
For pharmaceutical importers, the practical consequence is stacking complexity. A covered branded product from a standard tier country can now face its most favored nation rate, the applicable forced labor Section 301 duty, and the new Section 232 pharmaceutical duty on the same entry line, each with its own scope rules and exclusions. Customs brokers report that entry rejections and requests for information have climbed across the board this summer as CBP systems and importer software struggle to keep pace with the pace of new tariff programs, and the pharmaceutical action adds patent status and FDA listing status to the data elements that now matter at the border.
Mitigation tools exist, but each comes with caveats. Foreign trade zones allow importers to defer duties until goods enter United States commerce, though recent proclamations have required privileged foreign status that locks in duty rates at admission. Duty drawback can return duties on goods that are subsequently exported, a meaningful option for manufacturers who import ingredients and export finished products. Bonded warehousing defers the duty decision entirely, an attractive holding pattern for companies that expect their exemption or pricing negotiations to conclude favorably within months. Trade counsel caution that every one of these strategies requires documentation discipline that many pharmaceutical importers, long accustomed to duty free treatment of medicines, have never needed before.
Reporting for this article draws on the April 2026 presidential proclamation and White House fact sheet, client advisories from Arnall Golden Gregory, Crowell & Moring, Ropes & Gray, and Foley Hoag, analysis from PharmaSource and the Mallory Group, tariff trackers maintained by OIA Global and the Tax Foundation, and the Diaz Trade Law monthly trade roundup published July 31, 2026.